1: Predictors of metastatic disease afterprostate brachytherapy. Forsythe K, Burri R, Stone N, Stock RG. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):645-52.Epub
2011 Dec 2. PubMed PMID: 22137025.
2: Long-term outcome and toxicity ofsalvage brachytherapy for local failure after initial radiotherapy for prostatecancer. Burri RJ, Stone NN, Unger P, Stock RG. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1338-44. PubMed PMID:20138442.
3. Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity. Kao J, Cesaretti JA, Stone NN, Stock RG. Curr Urol Rep. 2011 Jun;12(3):237-42.
Review. PMID: 21399887
4. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol
Biol Phys. 2010 Aug 1;77(5):1315-21. Epub 2010 Jan 13. PMID: 20044216
5. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG. J Urol. 2010 Feb;183(2):634-9. Epub 2009
Dec 16. PMID: 20018308
6. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation
cause increased urinary, rectal, and sexual morbidity? Stone NN, Cesaretti JA, Rosenstein B, Stock RG. Brachytherapy. 2010 Apr-Jun;9(2):114-8. Epub 2009
Oct 30. PMID: 19879812
7. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and
oncologic outcomes. Stone NN, Stock RG, Cesaretti JA, Unger P. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):355-60.
Epub 2009 Jul 23. PMID: 19632069
8. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy
and hormonal therapy. Stock RG, Cesaretti JA, Hall SJ, Stone NN. BJU Int. 2009 Dec;104(11):1631-6. Epub 2009 Jun 2.
PMID: 19493260
9. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys.
2009 Sep 1;75(1):16-22. Epub 2009 Mar 14. PMID: 19289266
10. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined
with hormonal therapy and/or external beam radiotherapy. Stock RG, Klein TJ, Cesaretti JA, Stone NN. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):753-8.
Epub 2008 Dec 10. PMID: 19084351
11. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time
low-dose-rate prostate brachytherapy. Solan AN, Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1468-74.
Epub 2008 Oct 14. PMID: 18922652
12. Distant and local recurrence in patients with biochemical failure after prostate brachytherapy. Stock RG, Cesaretti JA, Unger P, Stone NN. Brachytherapy. 2008 Jul-Sep;7(3):217-22. PMID: 18635024
13. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse
effects resulting from radiotherapy for prostate cancer. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone
NN, Ostrer H, Rosenstein BS. Radiat Res. 2008 Jul;170(1):49-59. PMID: 18582155
14. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Kao J, Stone NN, Lavaf A, Dumane V, Cesaretti JA, Stock RG. Int J Radiat Oncol Biol Phys. 2008
Jan 1;70(1):96-101. Epub 2007 Nov 5. PMID: 17980505
15. Brachytherapy for the treatment of prostate cancer. Cesaretti JA, Stone NN, Skouteris VM, Park JL, Stock RG. Cancer J. 2007 Sep-Oct;13(5):302-12.
Review. PMID: 17921729
16. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with
radiotherapy. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, Stone NN,
Ostrer H, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):752-9. Epub 2007 Aug 8. PMID: 17689884
17.
Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment:
analysis at > or = 7 years of follow-up. Cesaretti JA, Kao J, Stone NN, Stock RG. BJU Int. 2007 Aug;100(2):362-7. PMID: 17617140
18. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Cesaretti JA, Stock RG, Atencio DP, Peters SA, Peters CA, Burri RJ, Stone NN,
Rosenstein BS. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1410-6. Epub 2007 May 9. PMID: 17490827
19.
Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined
103Pd implantation and external beam radiation for T3c prostate cancer. Ho AY, Burri RJ, Jennings GT, Stone NN, Cesaretti JA, Stock RG. Brachytherapy.
2007 Jan-Mar;6(1):38-43. PMID: 17284384
20. Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Zagar TM, Stock RG, Cesaretti JA, Stone NN. Brachytherapy. 2007 Jan-Mar;6(1):26-33. PMID: 17284382
21. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Stock RG, Ho A, Cesaretti JA, Stone NN. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):389-94.
PMID: 16965991
22. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Peters CA, Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):424-9.
Epub 2006 Aug 2. PMID: 16887295
23. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K,
Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS. Int J Radiat Oncol Biol
Phys. 2006 Jul 1;65(3):646-55. PMID: 16751059
24. Adjuvant radiation with modern techniques is the standard of care for stage III thymoma. Cesaretti JA. Ann Thorac Surg. 2006 Mar;81(3):1180-1; author reply 1181-2. No abstract available.
PMID: 16488766
25. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti JA, Atencio DP, Green
S, Formenti SC, Stock RG, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):776-83. Epub 2005 Dec 9. PMID: 16338099
26. Disease-specific survival following the brachytherapy management of prostate cancer. Stock RG, Cesaretti JA, Stone NN. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):810-6. Epub 2005
Nov 23. PMID: 16309852
27. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33.
Epub 2005 Oct 19. PMID: 16242258
28. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Cesaretti JA, Stock RG, Lehrer S, Atencio DA, Bernstein JL, Stone NN, Wallenstein S, Green S,
Loeb K, Kollmeier M, Smith M, Rosenstein BS. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):196-202. PMID: 15629612
29. Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):648-53. PMID:
15380602
30. Combined modality treatment in the management of high-risk prostate cancer. Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN. Int J Radiat Oncol Biol Phys. 2004 Aug
1;59(5):1352-9. PMID: 15275720
31. Urinary symptom flare following I-125 prostate brachytherapy. Cesaretti JA, Stone NN, Stock RG. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1085-92. PMID:
12829146
32. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Stock RG, Stone NN, Cesaretti JA. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):448-53. PMID:
12738319
33. Intraprostatic fiducials for localization of the prostate gland: The distance between markers as a surrogate for marker stability. Kupelian PA, Willoughby TR, Meeks SL, Forbes A, Wagner TH, Maach M, Langen KM. 2005 Aug 1. PMID:
16029784
34. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the
prostate. Terk MD, Stock RG, Stone NN. 1998 Oct. PMID: 9751358
35. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. Am J Clin Oncol. 2010 Oct;33(5):481-8.
PMID:19952715
36. In vivo verification of proton beam path by using post-treatment PET/CT imaging. Hsi WC, Indelicato DJ, Vargas C, Duvvuri S, Li Z, Palta J. Med Phys. 2009 Sep;36(9):4136-46. PMID:19810487
37. Cine-magnetic resonance imaging assessment of intrafraction motion for prostate cancer patients supine or prone with and without
a rectal balloon. Vargas C, Saito AI, Hsi WC, Indelicato D, Falchook A, Zengm Q, Oliver K, Keole S, Dempsey J. Am
J Clin Oncol. 2010 Feb;33(1):11-6. PMID:19730351
38. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Chera BS, Vargas C, Morris CG, Louis D, Flampouri S, Yeung D, Duvvuri S, Li Z, Mendenhall NP.
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):994-1002. Epub 2009 Jul 18. PMID:19619961
39. Proton therapy for prostate cancer treatment employing online image guidance and an action level threshold. Vargas C, Falchook A, Indelicato D, Yeung A, Henderson R, Olivier K, Keole S, Williams C, Li Z,
Palta J. Am J Clin Oncol. 2009 Apr;32(2):180-6. PMID:19307953
40. Dosimetric uncertainty in prostate cancer proton radiotherapy. Lin L, Vargas C, Hsi W, Indelicato D, Slopsema R, Li Z, Yeung D, Horne D, Palta J. Med Phys. 2008
Nov;35(11):4800-7. PMID:19070212
41. Dose-volume differences for computed tomography and magnetic resonance imaging segmentation and planning for proton prostate
cancer therapy. Yeung AR, Vargas CE, Falchook A, Louis D, Olivier K, Keole S, Yeung D, Mendenhall NP, Li Z. Int
J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1426-33. Epub 2008 Aug 30. PMID:18762391
42. Image guidance based on prostate position for prostate cancer proton therapy. Vargas C, Wagner M, Indelicato D, Fryer A, Horne D, Chellini A, McKenzie C, Lawlor P, Mahajan
C, Li Z, Lin L, Keole S. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1322-8. Epub 2008 May 28. PMID:18472365
43.
Proton therapy coverage for prostate cancer treatment. Vargas C, Wagner M, Mahajan C, Indelicato D, Fryer A, Falchook A, Horne D, Chellini A, McKenzie
C, Lawlor P, Li Z, Lin L, Keole S. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1492-501. PMID:18374228
44.
Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate
cancer. Vargas C, Mahajan C, Fryer A, Indelicato D, Henderson RH, McKenzie C, Horne D, Chellini A, Lawlor
P, Li Z, Oliver K, Keole S. Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1110-6. PMID:17967305
45. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy:
dose-volume analysis of a phase II dose-escalation study. Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, Gustafson G, Vicini F, Martinez A,
Kestin LL. Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1100-9. PMID:17967304
46. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, McKenzie C, Lawlor P, Henderson
R, Li Z, Lin L, Olivier K, Keole S. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):744-51. Epub 2007 Sep 27. PMID:17904306
47. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based
and dose-volume-based normal tissue complication probability models. Söhn M, Yan D, Liang J, Meldolesi E, Vargas C, Alber M. Int J Radiat Oncol Biol Phys. 2007
Mar 15;67(4):1066-73. Epub 2007 Jan 26. PMID: 17258870
48. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without
pelvic RT and high-dose radiation using high dose rate brachytherapy. Vargas CE, Demanes J, Boike TP, Barnaba MC, Skoolisariyaporn P, Schour L, Gustafson GS, Gonzalez
J, Martinez AA. Am J Clin Oncol. 2006 Oct;29(5):451-7. PMID: 17023778
49. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Vargas CE, Martinez AA, Boike TP, Spencer W, Goldstein N, Gustafson GS, Krauss DJ, Gonzalez J.
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):416-23. Epub 2006 Jul 31. PMID: 16879929
50. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally
to account for microscopic extension? Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, Kernen KM, Hollander JB, Gonzalez
JA, Martinez AA, Vicini FA, Kestin LL. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):999-1007. Epub 2006 Jun 5. PMID:16750320
51. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to
achieve rectal isotoxicity. Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA. Int J Radiat Oncol
Biol Phys. 2005 Sep 1;63(1):141-9. PMID:16111582
52. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate
prostate brachytherapy. Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A. J Urol. 2005
Sep;174(3):882-7. PMID:16093980
53. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated
hypofractionated regime. Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri
G, Gonzalez J. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31. PMID:16029788
54. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided
radiotherapy. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson
GS, Chen PY, Vicini FA, Wong JW. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. Review. PMID:16029785
55.
Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with
high-dose radiation. Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nürnberg N, Schour L, Martinez
A. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1474-82. Epub 2005 Jun 20. PMID:15964706
56. Assessment of residual error for online cone-beam CT-guided treatment of prostate cancer patients. Létourneau D, Martinez AA, Lockman D, Yan D, Vargas C, Ivaldi G, Wong J. Int J Radiat Oncol
Biol Phys. 2005 Jul 15;62(4):1239-46. PMID:15913917
57. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A. J Urol. 2005 May;173(5):1456-62.
Review. PMID:15821460
58. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic
features. Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24.
PMID:15708249
59.High dose rate brachytherapy in the treatment of prostate cancer. Vicini F, Vargas C, Gustafson G, Edmundson G, Martinez A. World J Urol. 2003 Sep;21(4):220-8.
Epub 2003 Aug 5. Review. PMID:12905008
60. The role of high-dose rate brachytherapy in locally advanced prostate cancer. Vicini FA, Vargas C, Edmundson G, Kestin L, Martinez A. Semin Radiat Oncol. 2003 Apr;13(2):98-108.
Review. PMID: 12728439
BACK TO TOP
